All News

Trump said imported generic drugs will face no tariff for 2 years starting August 1, then a 100% rate in 2028 and 200% in 2029, extending his trade fight to the drugs most Americans actually take.

New York City health officials confirmed a 5th fatality in the Upper East Side Legionnaires' disease outbreak.

This research reinforces that fixed-duration, chemotherapy-free regimens can offer both a tolerability and a patient-experience advantage over CIT.

FDA approves zidesamtinib for ROS1-positive NSCLC after prior TKIs, offering a new option for resistant and CNS-active disease.

A Boston population health roundtable examined why patients with atopic dermatitis often stayed undertreated despite an expanding set of therapeutics.

A digitally enabled quality improvement strategy lowered LDL-C and boosted treatment intensification, though most patients still missed guideline targets.

Left atrial (LA) strain impairment in dilated cardiomyopathy was driven by ventricular dilation, not left bundle branch block.

Diagnostic delays and access barriers continue to affect patients with MS, especially in under-resourced areas, World Brain Day highlights.

Cognitive rehabilitation significantly improved goal attainment and satisfaction in adults with long COVID-related cognitive impairment.

Women with PMOS had more than 4 times the adjusted ASCVD risk of matched peers, and traditional risk factors explained only about a third of the gap.

Public health groups sued the FDA, alleging its e-cigarette enforcement guidance violates federal tobacco law and risks youth nicotine addiction.

AI-guided breast screening is advancing faster than coverage policy, guidelines, and imaging capacity—raising questions about who qualifies and who pays.

CMS proposes major Medicare reforms to ACOs, physician pay, and MIPS reporting, aiming to reward outcomes over service volume by 2029.

GLP-1 use in adolescents and young adults with obesity rose to 96.1% as bariatric surgery fell by two-thirds, new JAMA Pediatrics data show.

This analysis, presented by Rahul Banerjee, MD, FACP, at EHA 2026, builds on data that supported the FDA’s March 2026 approval of teclistamab.

Paul Hahn, MD, says access and reimbursement, not innovation, are retina care’s biggest barriers and outlines where the field is headed next.

CRC treatment delays were linked to higher metastatic risk, but meaningful thresholds varied by treatment pathway, supporting tailored benchmarks.

Global early-onset CKD mortality declined from 1990 to 2021, but incidence rose, highlighting persistent disparities and prevention needs.

US drug shortages rose to 227 in Q2 2026, led by a severe ifosfamide shortage.

Existing rebates and manufacturers' gaming risk may limit these gains.

Patients with a history of nonmelanoma skin cancer had a 548% greater likelihood to develop another skin cancer vs those with no cancer history.

Hepatitis B and C prevention programs improve detection, treatment, and liver outcomes, but screening, care access, and implementation gaps remain.

AI phenotyping identified cardiovascular and kidney disease as key predictors of rapid fibrosis progression, complications, and higher costs in MASH.

The AI model matched or beat expert agreement on sleep arousal scoring, outperforming interscorer reliability across 10 scorers in an independent dataset.

Dry eye disease primarily causes stinging in the eye and blurry vision, which can affect quality of life.

A common, underdiagnosed genetic disorder, hereditary hemochromatosis is costly when caught late and simple to treat when caught early.

Hospital-at-home meets inpatient safety, PBM insulin settlement lowers costs, SNAP narrows screening gaps, and execs warn innovation outpaces reimbursement.

Designated teams, standardized SOPs, and scalable workflows are essential before a community practice's first bispecific dose.